에 대한 최신 뉴스 Waters (NYSE:WAT) 주식

Waters

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.

Reddit (RDDT) Vs. Trump's DJT: How 2 High-Profile Social Media Stocks Have Fared Since March Listings

EXEL

GRMN

MBLY

PAYC

RBLX

RDDT

SNAP

TEAM

TWLO

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 레딧(NYSE:RDDT)의 주가는 회사가 3분기 실적을 보고하고 예상보다 높은 4분기 매출 지침을 발표한 후 38.86% 상승했으며 많은 분석가들이 주가 예측을 상향했다.

레딧, 로블록스 및 가민은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 28일-11월 1일)

Waters Corp

WATERCO LTD by WATERCO LTD.

Energous Corp

WATERMARK LODGING TRUST A by Watermark Lodging Trust Inc.

WATCHES OF SWITZERLAND G by Watches of Switzerland Group PLC

Watches of Switzerland Group PLC

WATER INTELLIGENCE PLC by Water Intelligence PLC

Water Intelligence PLC

WATER OASIS GROUP LTD by Water Oasis Group Ltd.

Water Oasis Group Ltd

WATER TECH INTL by Water Technologies International,Inc.

Water Technologies International Inc

WATER WAYS TECHS INC by WATER WAYS TECHNOLOGIES INC

Water Ways Technologies Inc

WATERPURE INTL INC by WaterPure International, Inc.

WaterPure International Inc

Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A Ordinary Shares)

Waterdrop Inc

Waterloo Brewing Ltd

Waterstone Financial, Inc. - Common Stock

Waterstone Financial Inc

Waton Financial Limited - Ordinary Shares

Waton Financial Ltd

Watsco Inc

Watts Co Ltd

Watts Water Technologies, Inc. Class A Common Stock

Watts Water Technologies Inc

Baird analyst Catherine Ramsey maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Outperform and lowers the price target from $407 to $355.

News

Price Target

Analyst Ratings

Baird Maintains Outperform on Waters, Lowers Price Target to $355

WIIM

ACHR

AMSC

AMTM

BEEM

BlackSky Technology Inc. Class A Common Stock

BKSY

BLDR

CARR

CEA INDUSTRIES INC by CEA Industries Inc.

CEAD

CHPT

CNTM

CRGE

CTRI

ENVX

EOSE

FLNC

HKPD

HTCO

HUBB

ICON

IESC

ILAG

LICN

LNZA

LUNR

MVST

NPWR

NRGV

NVVE

PLUG

POWL

SKYX

TFII

TITN

TPIC

UPWK

Shares of companies in the broader industrial sector are trading lower as stocks pull back after surging Wednesday following President Trump's tariff pause announcement.

Barclays analyst Luke Sergott maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Equal-Weight and lowers the price target from $400 to $350.

Barclays Maintains Equal-Weight on Waters, Lowers Price Target to $350

Keybanc analyst Paul Knight upgrades Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) from Sector Weight to Overweight and announces $460 price target.

Upgrades

Keybanc Upgrades Waters to Overweight, Announces $460 Price Target

Across the recent three months, 7 analysts have shared their insights on Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Waters, revealing an average target of $414.57, a high estimate of $450.00, and a low estimate of $390.00. Witnessing a positive shift, the current average has risen by 3.05% from the previous average price target of $402.29.
<img src="https://www.benzinga.com/files/images/story/2025/1743012101_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Waters by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$407.00</td>
<td>$396.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$390.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$450.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$420.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Elizabeth Garcia</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$410.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$410.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$415.00</td>
<td>$360.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Waters. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Waters's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Waters's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Waters analyst ratings.</a>
<h2>Unveiling the Story Behind Waters</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
<h3>Waters: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Waters displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 6.5%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Waters's net margin is impressive, surpassing industry averages. With a net margin of 26.51%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Waters's ROE excels beyond industry benchmarks, reaching 13.49%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Waters's ROA excels beyond industry benchmarks, reaching 5.11%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.93, Waters adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Waters Through The Eyes Of 7 Analysts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Catherine Ramsey upgraded the rating for Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) from Neutral to Outperform and raised the price target from $396 to $407. Waters shares closed at $368.53 on Tuesday. <a href="https://www.benzinga.com/quote/wat/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods analyst Timothy Switzer upgraded ConnectOne Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNOB#NASDAQ">CNOB</a>) from Market Perform to Outperform and raised the price target from $31 to $32. ConnectOne Bancorp shares closed at $23.73 on Tuesday. <a href="https://www.benzinga.com/quote/CNOB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Devin McDermott upgraded the rating for Range Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) from Underweight to Equal-Weight and increased the price target from $40 to $49. Range Resources shares closed at $40.14 on Tuesday. <a href="https://www.benzinga.com/quote/rrc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst James Faucette upgraded Global-E Online Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) from Equal-Weight to Overweight but lowered the price target from $55 to $46. Global E Online shares closed at $38.26 on Tuesday. <a href="https://www.benzinga.com/quote/GLBE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jeffrey Zekauskas upgraded Ashland Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) from Neutral to Overweight and raised the price target from&nbsp;$68&nbsp;to&nbsp;$71. Ashland shares closed at $56.93 on Monday. &nbsp;<a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Image: Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

AKYA

CNOB

GLBE

This Waters Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Baird analyst Catherine Ramsey upgrades Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) from Neutral to Outperform and raises the price target from $396 to $407.

Baird Upgrades Waters to Outperform, Raises Price Target to $407

Throughout the last three months, 8 analysts have evaluated Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Waters, presenting an average target of $419.38, a high estimate of $450.00, and a low estimate of $390.00. This upward trend is evident, with the current average reflecting a 4.1% increase from the previous average price target of $402.86.
<img src="https://www.benzinga.com/files/images/story/2025/1741284062_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Waters by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$390.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$450.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$420.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>Elizabeth Garcia</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$410.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$410.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$415.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$430.00</td>
<td>-</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$430.00</td>
<td>$400.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Waters. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Waters's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Waters analyst ratings.</a>
<h2>All You Need to Know About Waters</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
<h3>Key Indicators: Waters's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Waters's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 6.5%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Waters's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 26.51% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Waters's ROE stands out, surpassing industry averages. With an impressive ROE of 13.49%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.11%, the company showcases effective utilization of assets.
Debt Management: Waters's debt-to-equity ratio is below the industry average at 0.93, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

8 Analysts Have This To Say About Waters

Waters's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) short percent of float has fallen 18.89% since its last report. The company recently reported that it has 1.30 million shares sold short, which is 2.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.54 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Waters Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741278631_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Waters has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Waters's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Waters's peer group average for short interest as a percentage of float is 5.72%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is the Market Bullish or Bearish on Waters?

JP Morgan analyst Rachel Vatnsdal maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Neutral and raises the price target from $380 to $390.

JP Morgan Maintains Neutral on Waters, Raises Price Target to $390

Scotiabank analyst Sung Ji Nam upgrades Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) from Sector Perform to Sector Outperform and raises the price target from $430 to $450.

Scotiabank Upgrades Waters to Sector Outperform, Raises Price Target to $450

Wells Fargo analyst Brandon Couillard maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Overweight and raises the price target from $415 to $420.

Wells Fargo Maintains Overweight on Waters, Raises Price Target to $420

UBS analyst Elizabeth Garcia maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Neutral and raises the price target from $405 to $410.

UBS Maintains Neutral on Waters, Raises Price Target to $410

B of A Securities analyst Derik De Bruin maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Neutral and lowers the price target from $430 to $410.

B of A Securities Maintains Neutral on Waters, Lowers Price Target to $410

Waters shares are trading lower after the company issued FY25 and Q1 adjusted EPS guidance below estimates.

Currency translation is expected to decrease first&nbsp;quarter sales growth by approximately 3.0%. The resulting first&nbsp;quarter 2025 reported sales growth is expected in the range of +1.0% to +4.0%.

Guidance

Waters Corp Expects Q1 2025 Constant Currency Sales Growth Of +4.0% To +7.0%, Adj EPS Of $2.17 - $2.25 (Est $2.42)

Currency translation is expected to decrease full-year sales growth by approximately 2.0%. The resulting full-year 2025 reported sales growth is expected in the range of +2.5% to +5.0%.
&nbsp;

Waters Corp Expects Full-year 2025 Constant Currency Sales Growth Of +4.5% To +7.0%, Adj EPS Of $12.70 - $13.00 (Est $12.85)

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) reported quarterly earnings of $4.10 per share which beat the analyst consensus estimate of $4.03 by 1.74 percent. This is a 13.26 percent increase over earnings of $3.62 per share from the same period last year. The company reported quarterly sales of $872.71 million which beat the analyst consensus estimate of $857.21 million by 1.81 percent. This is a 6.50 percent increase over sales of $819.47 million the same period last year.

Earnings

Earnings Beats

Waters Q4 2024 Adj EPS $4.10 Beats $4.03 Estimate, Sales $872.71M Beat $857.21M Estimate

ACRE

AEIS

AEMD

ALCO

ALKS

AMWL

ASND

ASPN

ATRC

AVXL

AYTU

BIIB

BROS

BXMT

CAMT

CGNX

CHEF

CNCK

CNDT

COOP

CRBG

CRSR

CRWS

CSCO

CTRE

CWST

DENN

EPRT

EQIX

FCPT

FSLY

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HOOD

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PEGA

PLMR

PODC

PXLW

PYPD

QDEL

QMCO

QTWO

Earnings Scheduled For February 12, 2025

Barclays analyst Luke Sergott upgrades Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) from Underweight to Equal-Weight and raises the price target from $360 to $415.

Barclays Upgrades Waters to Equal-Weight, Raises Price Target to $415

Commodities

Press Releases

Waters Corporation Named to Dow Jones Sustainability Index for the Fourth Consecutive Year

Waters Corporation to Host Investor Day on March 5, 2025

Waters Corporation Schedules Fourth Quarter 2024 Earnings Conference Call

Innovative Waters TGA Smart-Seal Pans Enable Lower Cost, More Efficient Benchtop Analysis of Atmosphere-Sensitive Materials

Waters ElectroForce Apex 1 Instrument Offers Increased Versatility, Simplicity, and Speed to Mechanical Testing of Advanced Polymer Materials

Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2024 Financial Results

Waters Corporation to Present at the Leerink Partners Global Healthcare Conference

Waters Expands Alliance iS Bio HPLC Product Line with Photodiode Array Detector to Enhance Spectral Insights for Biopharma Development & QC

Waters Corporation Schedules First Quarter 2025 Earnings Conference Call

STAAR Surgical Announces Changes to Board of Directors

BAYRY

Comments

Waters

뉴스

에 대한 최신 뉴스 Waters (NYSE:WAT) 주식

일요일, 11월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌